Payment overview · 2025
General Payments
$229.98
10 reported records · 8 companies
Healthcare provider profile · identity verified
Daniel Dean Watson, NP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · MOUNT AIRY, NC · NPI 1730687476
Verified facts
What the public records show
CMS Open Payments records show Daniel Dean Watson, NP received $229.98 in general payments during 2025 across 10 reported records.
Gilead Sciences, Inc. accounted for 22.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Belbuca, Trelegy Ellipta, Ztlido.
Collegium Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BELBUCA as an associated drug or biological on 17475 records involving 4385 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Belbuca by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 287 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Eliquis by this doctor in 2024.
SCILEX PHARMACEUTICALS INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZTLido as an associated drug or biological on 6923 records involving 3060 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Ztlido by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $51.43 | 22.4% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $42.08 | 18.3% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $35.83 | 15.6% | 2 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $26.04 | 11.3% | 1 | 2025 |
| SCILEX PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $22.24 | 9.7% | 1 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $19.38 | 8.4% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $18.38 | 8.0% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $14.60 | 6.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $229.98 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $42.08 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $35.83 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $35.83 | 2 | 2025 |
Source payment records
|
|||||
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $26.04 | 1 | 2025 |
Source payment records
|
|||||
| ZTLido Normalized: ztlido |
Drug | SCILEX PHARMACEUTICALS INC. | $22.24 | 1 | 2025 |
Source payment records
|
|||||
| Belbuca Normalized: belbuca |
Drug | Collegium Pharmaceutical, Inc. | $19.38 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $18.38 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $14.60 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Belbuca belbuca |
2025 | Belbuca | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 57 | exact normalized | Medicare Part D |
| ZTLido ztlido |
2025 | Ztlido | 2024 | 93 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Collegium Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | BELBUCA open payments reported associated product |
CMS Open Payments — General Payments 17475 supporting records · 4385 recipient NPIs · example record 1224105020 |
Belbuca · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
57 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
287 | 51 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| SCILEX PHARMACEUTICALS INC. Exact reporting entity; no affiliate inference |
2025 | ZTLido open payments reported associated product |
CMS Open Payments — General Payments 6923 supporting records · 3060 recipient NPIs · example record 1242585247 |
Ztlido · 2024 Exact normalized brand match · 1 Part D row |
93 | 21 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Oxycodone Hcl | Oxycodone Hcl | 472 | 60 |
| Ozempic | Semaglutide | 372 | 69 |
| Mounjaro | Tirzepatide | 287 | 51 |
| Gabapentin | Gabapentin | 274 | 37 |
| Ondansetron Odt | Ondansetron | 273 | 63 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 268 | 36 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 186 | 22 |
| Buspirone Hcl | Buspirone Hcl | 160 | 28 |
| Atorvastatin Calcium | Atorvastatin Calcium | 156 | 52 |
| Omeprazole | Omeprazole | 141 | 35 |
| Baclofen | Baclofen | 126 | 32 |
| Farxiga | Dapagliflozin Propanediol | 120 | 31 |
| Clonazepam | Clonazepam | 113 | 15 |
| Glipizide | Glipizide | 111 | 22 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 109 | 33 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 107 | 16 |
| Tizanidine Hcl | Tizanidine Hcl | 105 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 102 | 32 |
| Tramadol Hcl | Tramadol Hcl | 102 | 22 |
| Losartan Potassium | Losartan Potassium | 100 | 25 |
| Lisinopril | Lisinopril | 98 | 24 |
| Levothyroxine Sodium | Levothyroxine Sodium | 93 | 24 |
| Ztlido | Lidocaine | 93 | 21 |
| Buprenorphine Hcl | Buprenorphine Hcl | 91 | 11 |
| Pregabalin | Pregabalin | 90 | 11 |
| Amlodipine Besylate | Amlodipine Besylate | 87 | 22 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 85 | 14 |
| Trazodone Hcl | Trazodone Hcl | 77 | 11 |
| Linzess | Linaclotide | 76 | 20 |
| Lorazepam | Lorazepam | 76 | 14 |
| Pantoprazole Sodium | Pantoprazole Sodium | 71 | 22 |
| Alendronate Sodium | Alendronate Sodium | 65 | 21 |
| Xtampza Er | Oxycodone Myristate | 61 | suppressed |
| Prednisone | Prednisone | 60 | 38 |
| Ezetimibe | Ezetimibe | 58 | 21 |
| Montelukast Sodium | Montelukast Sodium | 58 | 17 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 57 | 15 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 57 | 14 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 56 | 17 |
| Alprazolam | Alprazolam | 55 | suppressed |
| Lisdexamfetamine Dimesylate | Lisdexamfetamine Dimesylate | 54 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 52 | suppressed |
| Mirtazapine | Mirtazapine | 48 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 47 | 40 |
| Metoprolol Succinate | Metoprolol Succinate | 47 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 45 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 43 | 12 |
| Suboxone | Buprenorphine Hcl/Naloxone Hcl | 41 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 38 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 37 | suppressed |
| Lidocaine | Lidocaine | 36 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 34 | 12 |
| Lactulose | Lactulose | 34 | 12 |
| Movantik | Naloxegol Oxalate | 34 | suppressed |
| Furosemide | Furosemide | 32 | 13 |
| Potassium Chloride | Potassium Chloride | 32 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 31 | suppressed |
| Belbuca | Buprenorphine Hcl | 30 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 30 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 26 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 23 | suppressed |
| Constulose | Lactulose | 22 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 22 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 22 | suppressed |
| Rybelsus | Semaglutide | 22 | suppressed |
| Allopurinol | Allopurinol | 21 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 21 | 16 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 20 | suppressed |
| Diazepam | Diazepam | 20 | suppressed |
| Jardiance | Empagliflozin | 20 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 20 | suppressed |
| Repatha Sureclick | Evolocumab | 20 | suppressed |
| Fentanyl | Fentanyl | 19 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 19 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 18 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 18 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 18 | suppressed |
| Rayos | Prednisone | 18 | suppressed |
| Sucralfate | Sucralfate | 18 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 18 | suppressed |
| Eliquis | Apixaban | 17 | suppressed |
| Fluconazole | Fluconazole | 17 | 14 |
| Metoprolol Tartrate | Metoprolol Tartrate | 17 | suppressed |
| Mupirocin | Mupirocin | 17 | 12 |
| Sumatriptan Succinate | Sumatriptan Succinate | 17 | suppressed |
| Topiramate | Topiramate | 16 | suppressed |
| Vraylar | Cariprazine Hcl | 16 | suppressed |
| Atenolol | Atenolol | 15 | suppressed |
| Celecoxib | Celecoxib | 15 | suppressed |
| Lubiprostone | Lubiprostone | 15 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 15 | suppressed |
| Simvastatin | Simvastatin | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 14 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 14 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Oxycontin | Oxycodone Hcl | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Levofloxacin | Levofloxacin | 13 | 11 |
| Lovastatin | Lovastatin | 13 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 13 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 13 | suppressed |
| Trulicity | Dulaglutide | 13 | suppressed |
| Azelastine-Fluticasone | Azelastine/Fluticasone | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 12 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 12 | suppressed |
| Famotidine | Famotidine | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Metformin Hcl | Metformin Hcl | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Vyvanse | Lisdexamfetamine Dimesylate | 12 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | suppressed |
| Azithromycin | Azithromycin | 11 | suppressed |
| Brilinta | Ticagrelor | 11 | suppressed |
| Cephalexin | Cephalexin | 11 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 11 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $229.98 · 10 records | Gilead Sciences, Inc. | Belbuca, CAPLYTA, NURTEC ODT, Senza, TRELEGY ELLIPTA, ZAVZPRET, ZEPBOUND, ZTLido | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Belbuca play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Collegium Pharmaceutical, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error